News Celgene files AML pill after fast-track trial The FDA has accepted Celgene’s filing for enasidenib.
News Novartis drug gets fast US review in AML Midostaurin also under review in rare disease systemic mastocytosis
Partner Content Partner Content Positive PIII results for VYXEOS revealed at ASCO Building on the announcement made in March of this year, Celator Pharmaceuticals has today (June 4th) presented the Phase III (PIII) findings for its combination therapy VYXEOS (cytarabine and daun
Oncology ASCO 2026: Chinese firms take a front seat in oncology, with... Dr Li Mao and Dr Giovanni Selvaggi of Betta Pharmaceuticals and Xcovery Holdings discuss their novel ALK inhibitor and the Chinese biotech landscape.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
